$ANIX

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

Anixa Biosciences (ANIX) President, COO & CFO Michael Catelani bought 5,500 shares on 2026-09-30, increasing his holdings to 50,000. The company has seen 18 insider buys and no sells in the past year. ANIX shares traded at $2.84, giving it a market cap of $100.99M. The company is a clinical-stage biotech focused on cancer treatments.

Catelani Michael (President, COO, & CFO) purchased 5,500 shares of Anixa Biosciences Inc (ANIX) at $2.84 on 2026-09-30.

Berkshire Hathaway bought Lennar (LEN) shares worth $136M. Insiders at Anixa (ANIX), DeFi (DFDV), Clipper (CLPR), and Harvard Apparatus (HRGN) made purchases. CrowdStrike (CRWD) CFO and Robinhood (HOOD) CEO sold shares worth $125M and $30M, respectively. Everpure (P) and Fastly (FSLY) insiders also sold shares.

KUMAR AMIT (Chief Executive Officer) purchased 7,000 shares of Anixa Biosciences Inc (ANIX) at $2.78 on 2026-09-24.

Baskies Arnold M purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $2.76 on 2026-09-24.

Titterton Lewis H jr purchased 49,036 shares of Anixa Biosciences Inc (ANIX) at $2.69 ($0.13M total) on 2026-09-23.

KUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $2.75 on 2026-09-10.